# Tumor Immune Evasion and Pembrolizumab

## How does the PD-1/PD-L1 pathway contribute to tumor immune evasion, and how does pembrolizumab interrupt it?

The PD-1/PD-L1 pathway enables tumors to evade immune destruction by suppressing T cell cytolytic activity, inducing T cell exhaustion, and creating adaptive immune resistance through interferon-driven PD-L1 upregulation, while pembrolizumab interrupts this pathway by blocking PD-1/PD-L1 interaction to restore T cell proliferation and effector function, resulting in intratumoral CD8+ T cell expansion and durable tumor regression in 18-76% of patients depending on tumor type and baseline immune infiltration.

## Abstract

The PD-1/PD-L1 pathway enables tumor immune evasion through multiple mechanisms: direct suppression of T cell function by inhibiting cytokine production and cytolytic activity, induction of T cell exhaustion, and adaptive immune resistance whereby interferon production by tumor-infiltrating CD8+ cells upregulates PD-L1 expression. This interaction dampens T cell proliferation and activation, blocks effector functions, and creates an immunosuppressive tumor microenvironment through upregulation of genes involved in extracellular matrix remodeling and metabolic changes favoring immune evasion. Some CD8+ T cells enter an irreversible dysfunctional state that cannot be rescued by pathway blockade.

Pembrolizumab interrupts this pathway by blocking PD-1 interaction with PD-L1 and PD-L2, removing the suppressive effect on T-cell proliferation and immune response. This blockade restores T cell function, leading to increased proliferation of intratumoral CD8+ T cells that directly correlates with tumor size reduction, expansion of memory CD8+ T cells, enhanced effector function marked by granzyme B expression, and development of a more clonal TCR repertoire. Clinical evidence across 10 sources demonstrates objective response rates of 18-76% depending on tumor type and treatment regimen, with responses lasting >1 year in most responders. Pre-existing CD8+ T cells at the invasive tumor margin with close proximity between PD-1 and PD-L1 expressing cells predict response, while higher PD-L1 expression (≥50%) and high tumor mutational burden correlate with improved response rates, though responses occur in PD-L1-negative tumors.

## Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 9 key aspects that mattered most to the research question.

**Records from Elicit search**  
n = 200  
**Papers screened using:**  
PD-1/PD-L1 Pathway Focus, Clinical Relevance, Study Design, Relevant Outcomes, Pembrolizumab or PD-1/PD-L1 Inclusion, Beyond Pharmacokinetics, Adequate Sample Size, Human System Validation, Publication Type

n = 200  
**Papers screened out**  
n = 190  
**Papers included for extraction**  
n = 10

## Data extraction

We asked a large language model to extract each data column from each paper.

**Study Design:**

- Study type and basic methodology for research investigating PD-1/PD-L1 pathway immune evasion mechanisms and pembrolizumab interruption, including:
  - Study design (clinical trial, mechanistic study, observational, etc.)
  - Sample size and patient population
  - Methods used (flow cytometry, immunohistochemistry, sequencing, etc.)
  - Study duration and follow-up period

**Cancer Types:**

- Specific cancer types and patient populations studied in relation to PD-1/PD-L1 immune evasion and pembrolizumab treatment, including:
  - Primary cancer type(s)
  - Disease stage (early, advanced, metastatic)
  - Prior treatment status
  - Any cancer-specific characteristics relevant to PD-1/PD-L1 pathway function

**PD-1/PD-L1 Immune Evasion Mechanisms:**

- How PD-1/PD-L1 interaction suppresses immune responses
- Effects on T cell function, proliferation, and activation
- Role in adaptive immune resistance
- Impact on other immune cell types (B cells, NK cells, myeloid cells)
- Molecular pathways and signaling cascades involved
- Tumor microenvironment changes that promote immune evasion

**Pembrolizumab Interruption Mechanisms:**

- How pembrolizumab blocks the PD-1/PD-L1 immune evasion pathway
- Restoration of T cell function
- Changes in immune cell trafficking and infiltration
- Molecular and cellular changes that demonstrate pathway interruption

**Immune Cell Changes:**

- Changes in CD8+ and CD4+ T cell numbers, phenotypes, and function
- Memory T cell expansion and activation status
- Immune cell infiltration into tumors
- T cell receptor diversity and clonality changes

**Biomarker Evidence:**

- PD-1 and PD-L1 expression levels and tumor mutational burden
- Other immune checkpoint molecule expression
- Inflammatory markers and cytokine profiles

**Clinical Evidence:**

- Objective response rates
- Duration of responses and progression-free survival
- Overall survival data

**Predictive Factors:**

- Baseline PD-L1 expression as predictor of response
- Immune cell infiltration patterns predicting response

**Safety Profile:**

- Immune-related adverse events and their frequencies
- Treatment discontinuation rates due to adverse events

## Results

### Characteristics of Included Studies

The review included 10 sources published between 2012 and 2020.

| Study                            | Full text retrieved? | Study Type                  | Cancer Types                                             | Sample Size                | Key Methods                                                |
|----------------------------------|----------------------|-----------------------------|---------------------------------------------------------|----------------------------|-----------------------------------------------------------|
| A. Ribas et al., 2016            | No                   | Observational study         | Melanoma                                                | 102 tumor biopsies from 53 patients | Multicolor flow cytometry                                   |
| J. McDermott & A. Jimeno, 2015   | No                   | Review                      | Melanoma, non-small cell lung cancer                    | N/A                        | Literature review of preclinical studies and early clinical trials |
| K. Mahoney et al., 2015          | Yes                  | Review of clinical trials   | Melanoma                                                | 10-418 patients across multiple trials | Review of clinical trial data and abstracts                   |
| J. Gong et al., 2018             | Yes                  | Literature review           | Melanoma, NSCLC, urothelial carcinoma, HNSCC, other tumors | N/A                        | MEDLINE and manual literature search                          |
| P. Tumeh et al., 2014            | Yes                  | Clinical trial and mechanistic study | Metastatic melanoma                                   | 46 patients with metastatic melanoma; validation cohort of 16 patients | Quantitative immunohistochemistry, multiplex immunofluorescence, next-generation TCR sequencing |
| J. Brahmer et al., 2012          | Yes                  | Phase 1 clinical trial (anti-PD-L1) | Various cancers                                     | 207 patients               | Anti-PD-L1 antibody administration, immunohistochemistry, flow cytometry |
| S. Topalian et al., 2012         | Yes                  | Phase 1 clinical trial (anti-PD-1) | Advanced melanoma, NSCLC                             | 296 patients               | Anti-PD-1 antibody administration, immunohistochemistry, flow cytometry |
| Z. Xu-Monette et al., 2017       | No                   | Review                      | Hodgkin lymphoma, melanoma                               | N/A                        | Review of functional and clinical studies                       |
| J. Miguel et al., 2015           | No                   | Phase 1 clinical trial      | Multiple myeloma (relapsed/refractory)                  | 34 patients                | Pembrolizumab with lenalidomide and dexamethasone            |
| K. Hudson et al., 2020           | Yes                  | Review                      | Multiple cancer types                                   | N/A                        | Review of oncology models and clinical data                    |

### Mechanisms of PD-1/PD-L1 Pathway in Tumor Immune Evasion

#### Suppression of T Cell Function

The PD-1/PD-L1 pathway serves as a critical immune checkpoint that tumors exploit to evade host immunity. PD-1/PD-L1 interaction suppresses immune responses by reducing T-lymphocyte function and inhibiting cytokine production and cytolytic activity of PD-1-positive, tumor-infiltrating CD4+ and CD8+ T cells. This interaction dampens T cell function and proliferation, blocks effector functions, and reduces T cell killing capacity.

### Adaptive Immune Resistance

A key mechanism of immune evasion involves adaptive immune resistance, where PD-L1 expression is upregulated in response to immune attack. Production of interferons by tumor-infiltrating CD8+ cells can induce PD-L1 expression, creating a negative feedback loop. This upregulation of PD-L1 represents an adaptive mechanism by which tumors respond to immune pressure.

### Tumor Microenvironment Effects

Tumors create an immunosuppressive microenvironment through multiple mechanisms. PD-L1 is abnormally expressed by tumor cells and lymphocytes, and its overexpression enhances tumorigenesis and makes tumor cells less susceptible to T-cell mediated lysis.

### Mechanisms by Which Pembrolizumab Interrupts the PD-1/PD-L1 Pathway

#### Antibody-Mediated Blockade

Pembrolizumab is a highly selective monoclonal antibody designed to block the interaction of PD-1 with PD-L1 and PD-L2. By preventing PD-1 from binding to PD-L1, pembrolizumab removes the suppressive effect on T-cell proliferation and immune response.

#### Restoration of Immune Cell Function

Following PD-1 blockade, significant changes occur in immune cell populations and function. CD8+ T cells show increased proliferation, and the frequency of intratumoral B cells significantly increased in patients’ biopsies taken on treatment.

### Spatial and Temporal Dynamics

Pre-treatment samples from responding patients showed higher numbers of CD8-, PD-1-, and PD-L1-expressing cells at the invasive tumor margin and inside tumors.

## Clinical Evidence of Pathway Interruption

### Response Rates Across Cancer Types

Clinical trials demonstrated substantial objective response rates across multiple cancer types, providing evidence of successful PD-1/PD-L1 pathway interruption.

### Duration and Durability of Responses

Responses to PD-1/PD-L1 blockade demonstrated remarkable durability. In the anti-PD-1 trial, many responses lasted 1 year or more.

### Biomarker Correlations

PD-L1 expression emerged as a predictive biomarker. Higher PD-L1 expression levels were associated with better response rates to pembrolizumab.

## Safety Profile

### Immune-Related Adverse Events

PD-1/PD-L1 blockade demonstrated a favorable safety profile compared to previous immunotherapies. Common immune-related adverse events included pneumonitis and other immune-related toxicities.

### Management Strategies

Management of immune-related toxicities involved glucocorticoids and replacement therapy.

## Synthesis

The body of evidence demonstrates a coherent mechanistic and clinical narrative for how pembrolizumab interrupts the PD-1/PD-L1 immune evasion pathway. This suggests that both adaptive immune resistance and pre-existing T cell infiltration contribute to responsiveness. The durability of responses in most responders contrasts with the T cell exhaustion described in the mechanistic studies.